Characteristics of patients
| Characteristics . | All patients (N = 19) . |
|---|---|
| Age, median (range), y | 7 (3-25) |
| Sex, n (%) | |
| Male | 10 (53) |
| Female | 9 (47) |
| First relapse, n (%) | 13 (68) |
| VHR characteristics | 11 (58) |
| Refractory and VHR characteristics | 2 (10) |
| Second or subsequent relapse, n (%) | 6 (32) |
| Cytogenetic/molecular alterations, n (%) | |
| Hyperdiploidy | 5 (26) |
| KMT2A::MLLT3 | 1 (5) |
| TCF3::PBX1 | 1 (5) |
| BCR::ABL1 | 1 (5) |
| NONO::TFE3 | 1 (5) |
| ETV6::RUNX1 | 1 (5) |
| TP53mut | 1 (5) |
| 47 (+21) | 4 (21) |
| CNS involvement, n (%) | 2 (10) |
| Other extramedullary sites, n (%) | 3 (16) |
| Bones | 3 (16) |
| Kidneys | 1 (5) |
| Heart (left ventricle) | 1 (5) |
| Lymph nodes | 1 (5) |
| Median previous lines of therapy (range) | 2 (1-4) |
| Key previous treatments, n (%) | |
| Blinatumomab | 12 (63) |
| Inotuzumab ozogamicin | 6 (32) |
| Dasatinib | 1 (5) |
| Previous HSCT, n (%) | 6 (32) |
| Bridging therapy, n (%) | |
| None | 16 (84) |
| Low-dose chemotherapy | 3 (16) |
| Blast | |
| Median (range), % | 6.5 (0.1-50.0) |
| Patients with ≥5% blasts, n (%) | 10 (53) |
| Characteristics . | All patients (N = 19) . |
|---|---|
| Age, median (range), y | 7 (3-25) |
| Sex, n (%) | |
| Male | 10 (53) |
| Female | 9 (47) |
| First relapse, n (%) | 13 (68) |
| VHR characteristics | 11 (58) |
| Refractory and VHR characteristics | 2 (10) |
| Second or subsequent relapse, n (%) | 6 (32) |
| Cytogenetic/molecular alterations, n (%) | |
| Hyperdiploidy | 5 (26) |
| KMT2A::MLLT3 | 1 (5) |
| TCF3::PBX1 | 1 (5) |
| BCR::ABL1 | 1 (5) |
| NONO::TFE3 | 1 (5) |
| ETV6::RUNX1 | 1 (5) |
| TP53mut | 1 (5) |
| 47 (+21) | 4 (21) |
| CNS involvement, n (%) | 2 (10) |
| Other extramedullary sites, n (%) | 3 (16) |
| Bones | 3 (16) |
| Kidneys | 1 (5) |
| Heart (left ventricle) | 1 (5) |
| Lymph nodes | 1 (5) |
| Median previous lines of therapy (range) | 2 (1-4) |
| Key previous treatments, n (%) | |
| Blinatumomab | 12 (63) |
| Inotuzumab ozogamicin | 6 (32) |
| Dasatinib | 1 (5) |
| Previous HSCT, n (%) | 6 (32) |
| Bridging therapy, n (%) | |
| None | 16 (84) |
| Low-dose chemotherapy | 3 (16) |
| Blast | |
| Median (range), % | 6.5 (0.1-50.0) |
| Patients with ≥5% blasts, n (%) | 10 (53) |
CNS, central nervous system.